2-(3',5'-Dihydroxyphenyl)-2-hydroxyethylamin | 46049-55-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-(3',5'-Dihydroxyphenyl)-2-hydroxyethylamin
• 英文别名: D,L-1-(3',5'-Dihydroxyphenyl)-2-aminoethanol-(1)；5-[2-amino-1-hydroxyethyl]-1,3-benzenediol；1-(3',5'-dihydroxy-phenyl)-2-amino-ethanol；2-amino-1-(3,5-dihydroxyphenyl)ethanol；5-(2-Amino-1-hydroxyethyl)-1,3-benzenediol；5-(2-amino-1-hydroxyethyl)benzene-1,3-diol
• CAS: 46049-55-2
• 化学式: C₈H₁₁NO₃
• 分子量: 169.18
• InChiKey: VZVBXISLBQEWKU-UHFFFAOYSA-N

物化性质

• 沸点：
  443.5±30.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  86.7
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3',5'-Dihydroxyphenyl)-2-hydroxyethylamin 、 1-(异苯并二氢吡喃-1-基)-2-丙酮 生成 1-(3,5-Dihydroxyphenyl)-2-[2-(isochroman-1-yl)-1-methylethylamino]ethanol
  参考文献：
  名称：

  Arylalkylamine derivatives

  摘要：

  本发明涉及一种新型芳基烷基胺衍生物，其化学式表示为(I)##STR1##其中，X代表--O--，--CH.sub.2--或--NR.sup.3--，其中R.sup.3代表氢或低碳基；Y代表--NH--或##STR2##Z代表##STR3##其中R.sup.4代表氢或低碳基或##STR4##Q代表可选取代的芳基或可选取代的芳香族杂环基；每个R.sup.1和R.sup.2独立地代表氢或低碳基；每个m和n独立地代表0或1的整数；以及其药学上可接受的盐。化合物(I)及其药学上可接受的盐具有支气管扩张和抗过敏活性，可用于治疗支气管哮喘等呼吸系统疾病。

  公开号：

  US05128369A1

文献信息

• Ethanolamine compounds
  申请人：Glaxo Group Limited

  公开号：US04853381A1

  公开（公告）日：1989-08-01

  The invention provides compounds of the general formula (I) ##STR1## wherein Ar represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms, or the groups C.sub.1-6 alkyl, C.sub.1-6 alkoxy, nitro, --(CH.sub.2).sub.q R [where R is hydroxy, --NR.sup.3 R.sup.4 (where R.sup.3 and R.sup.4 each represent a hydrogen atom or a C.sub.1-4 alkyl group, or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O--, or --S-- or a group --NH-- or --N(CH.sub.3)--), --NR.sup.5 COR.sup.6 (where R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group, and R.sup.6 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenyl or --NR.sup.3 R.sup.4 group), --NR.sup.5 SO.sub.2 R.sup.7 (where R.sup.7 represents a C.sub.1-4 alkyl, phenyl or --NR.sup.3 R.sup.4 group), --COR.sup.8 (where R.sup.8 represents hydroxy, C.sub.1-4 alkoxy or --NR.sup.3 R.sup.4), --SR.sup.9 (where R.sup.9 is a hydrogen atom, or a C.sub.1-4 alkyl or phenyl group), --SOR.sup.9, SO.sub.2 R.sup.9, or --CN, and q represents an integer from 0 to 3], --(CH.sub.2).sub.r R.sup.10 (where R.sup.10 is a C.sub.1-4 alkoxy group and r represents an integer from 1 to 3) or --O(CH.sub.2).sub.t R.sup.11 (where R.sup.11 represents a hydroxy or C.sub.1-4 alkoxy group and t is an integer 2 or 3), or Ar is a phenyl ring substituted by an alkylenedioxy group of formula --O(CH.sub.2).sub.p O-- where p represents an integer 1 or 2; Q represents a group of formula ##STR2## where R.sup.a represents a hydrogen atom or a C.sub.1-3 alkyl group, R.sup.b represents ##STR3## and Rc represents ##STR4## where R.sup.d represents a straight or branched C.sub.2-3 alkylene chain; R.sup.1 and R.sup.2 each represent a hydrogen atom or a C.sub.1-3 alkyl group with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; X represents a C.sub.1-7 alkylene, C.sub.2-7 alkenylene or C.sub.2-7 alkynylene chain; and Y represents a bond or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is 2-10, and physiologically acceptable salts and solvates (e.g. hydrates) thereof. The compounds of formula (I) have a stimulant action at .beta..sub.2 -adrenoreceptors and are useful, in particular, in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

  本发明提供了一般式（I）的化合物：其中，Ar代表苯基，该苯基可以选择性地被一个或多个取代基所取代，所述取代基被选择自卤素原子，或基团C.sub.1-6烷基，C.sub.1-6烷氧基，硝基，--（CH.sub.2）.sub.qR [其中R是羟基，--NR.sup.3R.sup.4（其中R.sup.3和R.sup.4分别代表氢原子或C.sub.1-4烷基，或--NR.sup.3R.sup.4形成一个饱和的杂环氨基团，该团具有5-7个环成员并且在环中可以选择地包含一个或多个原子，所述原子被选择自--O--，或--S--或--NH--或--N（CH.sub.3）--） ，--NR.sup.5COR.sup.6（其中R.sup.5代表氢原子或C.sub.1-4烷基，R.sup.6代表氢原子或C.sub.1-4烷基，C.sub.1-4烷氧基，苯基或--NR.sup.3R.sup.4基团），--NR.sup.5SO.sub.2R.sup.7（其中R.sup.7代表C.sub.1-4烷基，苯基或--NR.sup.3R.sup.4基团），--COR.sup.8（其中R.sup.8代表羟基，C.sub.1-4烷氧基或--NR.sup.3R.sup.4），--SR.sup.9（其中R.sup.9是氢原子或C.sub.1-4烷基或苯基），--SOR.sup.9，SO.sub.2R.sup.9或--CN，q表示0到3的整数]，--（CH.sub.2）.sub.rR.sup.10（其中R.sup.10是C.sub.1-4烷氧基，r表示1到3的整数）或--O（CH.sub.2）.sub.tR.sup.11（其中R.sup.11代表羟基或C.sub.1-4烷氧基，t是2或3的整数），或Ar是一个苯环，该苯环被一个公式为--O（CH.sub.2）.sub.pO--的烷二氧基基团取代，其中p代表1或2；Q代表一个公式为的基团：其中R.sup.a代表氢原子或C.sub.1-3烷基，R.sup.b代表##STR3##和Rc代表##STR4##其中R.sup.d代表直链或支链C.sub.2-3烷基链；R.sup.1和R.sup.2分别代表氢原子或C.sub.1-3烷基，但总碳原子数不超过4；X代表C.sub.1-7烷基，C.sub.2-7烯基或C.sub.2-7炔基链；Y代表键或C.sub.1-6烷基，C.sub.2-6烯基或C.sub.2-6炔基链，但X和Y的总碳原子数为2-10，并且其生理上可接受的盐和溶剂（例如水合物）。公式（I）的化合物在.beta..sub.2-肾上腺素受体上具有兴奋作用，特别适用于治疗与可逆性气道阻塞相关的疾病，例如哮喘和慢性支气管炎。
• Ethanolamine Derivatives
  申请人：——

  公开号：EP0223410A3

  公开（公告）日：1987-11-19

  The invention provides compounds of the general formula (I)wherein Ar represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms, or the groups C1-6alkyl, C1-6alkoxy, nitro, -(CH2)qR [where R is hydroxy, -NR3R4 (where R3 and R4 each represent a hydrogen atom or a C1-4 alkyl group, or -NR3R4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from -O-or -S-or a group -NH-or -N-(CH3)-), -NR5COR6 (where R5 represents a hydrogen atom or a C1-4 alkyl group, and R6 represents a hydrogen atom or a C1-4 alkyl, C1-4 alkoxy, phenyl or -NR3R4 group), -NR5SO2R7 (where R' represents a C1-4 alkyl, phenyl or -NR3R4 group), -COR8 (where R8 represents hydroxy, C 1-4 alkoxy or -NR3R4), -SR9 (where R' is a hydrogen atom, or a C1-4 alkyl or phenyl group), -SOR9, -SO2R9 or -CN, and q represents an integer from 0 to 3], -(CH2) rR'° (where R10 is a C1-4 alkoxy group and r represents an integer from 1 to 3) or -O(CH2)tR11 (where R" represents a hydroxy or C1-4 alkoxy group and t is an integer 2 or 3), or Ar is a phenyl ring substituted by an alkylenedioxy group of formula -O(CH2)pO-where p represents an integer 1 or 2;Q represents a group of formula where Ra represents a hydrogen atom or a C1-3 alkyl group, Rb represents and Rc represents where R represents a straight or branched C2.3 alkylene chain; R' and R2 each represent a hydrogen atom or a C1-3 alkyl group with the proviso that the sum total of carbon atoms in R' and R2 is not more than 4;X represents a C1-7 alkylene, C2-7 alkenylene or C2.7alkynylene chain; andY represents a bond or a C1-6 alkylene, C2.6 alkenylene or C26 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is 2-10, and when X represents C 1-7 alkylene and Y represents a bond or C1-6alkylene, then the group Ar does not represent an unsubstituted phenyl group or a phenyl group substituted by one or two substituents selected solely from halogen atoms or C1-3 alkyl or C1-3 alkoxy groups or an alkylenedioxy group -O(CH2)pO-; and physiologically acceptable salts and solvates e.g. hydrates thereof.The compounds have a selective stimulant action at β2-adrenoreceptors and may be used, inter alia, in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

  该发明提供了通式（I）的化合物，其中Ar代表苯基，可选地被一个或多个取代基所取代，所述取代基选择自卤素原子，或基团C1-6烷基，C1-6烷氧基，硝基，-(CH2)qR [其中R为羟基，-NR3R4（其中R3和R4分别代表氢原子或C1-4烷基，或-NR3R4形成饱和的杂环氨基，其具有5-7个环成员并且在环中可选地包含一个或多个从-O-或-S-中选择的原子，或者一个-NH-或-N-(CH3)-基团），-NR5COR6（其中R5代表氢原子或C1-4烷基，R6代表氢原子或C1-4烷基，C1-4烷氧基，苯基或-NR3R4基团），-NR5SO2R7（其中R'代表C1-4烷基，苯基或-NR3R4基团），-COR8（其中R8代表羟基，C1-4烷氧基或-NR3R4基团），-SR9（其中R'是氢原子，或C1-4烷基或苯基），-SOR9，-SO2R9或-CN，并且q代表0到3的整数]，-( )rR'°（其中R10是C1-4烷氧基，r代表1到3的整数）或-O( )tR11（其中R"代表羟基或C1-4烷氧基，t是2或3的整数），或Ar是一个苯环，被一个通式为-O( )pO-的烷二氧基基团所取代，其中p代表1或2;Q代表一个式子，其中Ra代表氢原子或C1-3烷基，Rb代表，Rc代表，其中R代表直链或支链C2.3烷基链；R'和R2各代表氢原子或C1-3烷基，但是R'和R2的碳原子总数不超过4；X代表C1-7烷基，C2-7烯基或C2.7炔基链；和Y代表键或C1-6烷基，C2.6烯基或C26炔基链，但是当X代表C1-7烷基且Y代表键或C1-6烷基时，基团Ar不代表未取代的苯基或仅被卤素原子或C1-3烷基或C1-3烷氧基所取代的苯基或烷二氧基基团-O( )pO-;以及其生理上可接受的盐和溶剂化物，例如水合物。这些化合物在β2-肾上腺素受体上具有选择性的兴奋作用，可以用于治疗与可逆性气道阻塞有关的疾病，例如哮喘和慢性支气管炎。
• Phenethanolamine derivatives
  申请人：GLAXO GROUP LIMITED

  公开号：EP0317206A2

  公开（公告）日：1989-05-24

  The invention provides compounds of the general formula (I) and physiologically acceptable salts and solvates thereof, wherein Ar represents the group where Q¹ represents a straight or branched C₁₋₃alkylene group, where Q² represents a group R³CO-, R³NHCO-, R³R⁴NSO₂- or R⁵SO₂-, where R³ and R⁴ each represent a hydrogen atom or a C₁₋₃alkyl group, and R⁵ represents a C₁₋₃alkyl group, R represents a hydrogen atom or a C₁₋₃alkyl group; R¹ and R² each independently represent a hydrogen atom or a methyl or ethyl group; and k represents an integer from 1 to 8; m represents zero or an integer from 2 to 7, and; n represents an integer from 1 to 7 with the proviso that the sum total of k, m and n is 4 to 12; X represents an oxygen or sulphur atom, and; Y and Z each represent a bond, or an oxygen or sulphur atom with the proviso that when Y is a bond m is zero, or when Y represents an oxygen or sulphur atom m is an integer from 2 to 7, or when Y and Z each independently represent an oxygen or sulphur atom then n is an integer from 2 to 7; Q represents a naphthalenyl group which may optionally be substituted by one or two groups selected from C₁₋₄alkyl, C₁₋₄alkoxy, hydroxy and halogen. The compounds have a stimulant action at β₂-­adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

  本发明提供通式 (I) 的化合物 及其生理上可接受的盐和溶液，其中 Ar 代表基团 其中 Q¹ 代表直链或支链 C₁₋₃烷基、 其中 Q² 代表基团 R³CO-、R³NHCO-、R³R⁴NSO₂- 或 R⁵SO₂-，其中 R³ 和 R⁴ 各自代表氢原子或 C₁₋₃ 烷基，而 R⁵ 代表 C₁₋₃ 烷基、 R 代表氢原子或 C₁₋₃ 烷基； R¹ 和 R² 各自独立地代表氢原子或甲基或乙基；以及 k 代表 1 至 8 的整数； m 代表零或 2 至 7 的整数，以及 n 代表 1 至 7 的整数，但 k、m 和 n 的总和为 4 至 12； X 代表氧原子或硫原子，以及 Y 和 Z 各自代表一个键，或一个氧原子或硫原子，但当 Y 代表一个键时，m 为零，或当 Y 代表一个氧原子或硫原子时，m 为 2 至 7 的整数，或当 Y 和 Z 各自独立地代表一个氧原子或硫原子时，n 为 2 至 7 的整数； Q 代表萘基，可任选被一个或两个选自 C₁₋₄烷基、C₁₋₄烷氧基、羟基和卤素的基团取代。 这些化合物对 β₂-肾上腺素受体有刺激作用，可用于治疗与可逆性气道阻塞有关的疾病，如哮喘和慢性支气管炎。
• KOLARSKA, ZOFIA;SIENKIEWICZ, BARBARA
  作者：KOLARSKA, ZOFIA、SIENKIEWICZ, BARBARA

  DOI：——

  日期：——
• Ethanolamine derivatives
  申请人：GLAXO GROUP LIMITED

  公开号：EP0322164B1

  公开（公告）日：1993-09-22